Kezar Life Sciences Beheer

Beheer criteriumcontroles 2/4

De CEO Kezar Life Sciences is Chris Kirk, benoemd in Nov2023, heeft een ambtstermijn van 9.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.60M, bestaande uit 9.3% salaris en 90.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.59% van de aandelen van het bedrijf, ter waarde € 310.67K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2 jaar en 7.5 jaar.

Belangrijke informatie

Chris Kirk

Algemeen directeur

US$2.6m

Totale compensatie

Percentage CEO-salaris	9.3%
Dienstverband CEO	less than a year
Eigendom CEO	0.6%
Management gemiddelde ambtstermijn	2yrs
Gemiddelde ambtstermijn bestuur	7.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Chris Kirk's beloning veranderd ten opzichte van Kezar Life Sciences's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$96m
Jun 30 2024	n/a	n/a	-US$99m
Mar 31 2024	n/a	n/a	-US$101m
Dec 31 2023	US$3m	US$242k	-US$102m
Sep 30 2023	n/a	n/a	-US$88m
Jun 30 2023	n/a	n/a	-US$83m
Mar 31 2023	n/a	n/a	-US$74m
Dec 31 2022	US$2m	US$468k	-US$68m
Sep 30 2022	n/a	n/a	-US$64m
Jun 30 2022	n/a	n/a	-US$61m
Mar 31 2022	n/a	n/a	-US$58m
Dec 31 2021	US$2m	US$443k	-US$55m
Sep 30 2021	n/a	n/a	-US$51m
Jun 30 2021	n/a	n/a	-US$48m
Mar 31 2021	n/a	n/a	-US$45m
Dec 31 2020	US$880k	US$426k	-US$42m
Sep 30 2020	n/a	n/a	-US$40m
Jun 30 2020	n/a	n/a	-US$38m
Mar 31 2020	n/a	n/a	-US$37m
Dec 31 2019	US$2m	US$410k	-US$35m
Sep 30 2019	n/a	n/a	-US$31m
Jun 30 2019	n/a	n/a	-US$28m
Mar 31 2019	n/a	n/a	-US$26m
Dec 31 2018	US$962k	US$365k	-US$23m
Sep 30 2018	n/a	n/a	-US$20m
Jun 30 2018	n/a	n/a	-US$16m
Mar 31 2018	n/a	n/a	-US$11m
Dec 31 2017	US$745k	US$325k	-US$9m

Compensatie versus markt: De totale vergoeding ($USD 2.60M ) Chris } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 471.55K ).

Compensatie versus inkomsten: De vergoeding van Chris is gestegen terwijl het bedrijf verliesgevend is.

CEO

Chris Kirk (52 yo)

less than a year

Tenure

US$2,602,155

Compensatie

Dr. Christopher J. Kirk, also known as Chris, Ph.D. serves as Member of Scientific Advisory Board at Rain Oncology Inc. (formerly known as Rain Therapeutics Inc.) He is a Co-Founder of Kezar Life Sciences,...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Christopher Kirk	Co-Founder	less than a year	US$2.60m	0.59% € 310.7k
John Fowler	Co-Founder & Director	no data	US$4.83m	0.60% € 314.1k
Marc Belsky	CFO & Secretary	6.7yrs	US$2.01m	0.026% € 13.5k
Jack Taunton	Co-Founder	no data	geen gegevens	geen gegevens
Gitanjali Jain	Senior Vice President of Investor Relations & External Affairs	no data	geen gegevens	geen gegevens
Mark Schiller	Chief Legal Officer	5.6yrs	geen gegevens	0.025% € 13.0k
Joe Tedrick	Vice President of Human Resources	less than a year	geen gegevens	geen gegevens
Neel Anand	Senior Vice President of Research & Drug Discovery	2.6yrs	geen gegevens	geen gegevens
Zung To	Senior Vice President of Clinical Development	1.5yrs	geen gegevens	geen gegevens
Pattie Chiang	Senior VP & Corporate Controller	no data	geen gegevens	geen gegevens

2.0yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 2KZ0 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Christopher Kirk	Co-Founder	9.8yrs	US$2.60m	0.59% € 310.7k
John Fowler	Co-Founder & Director	9.8yrs	US$4.83m	0.60% € 314.1k
Michael Kauffman	Independent Director	7.9yrs	US$155.34k	0.087% € 45.9k
Franklin Berger	Independent Director	8.8yrs	US$141.22k	1.22% € 641.5k
Graham Cooper	Independent Chairman	7.1yrs	US$194.56k	0% € 0
Elizabeth Ijeoma Garner	Independent Director	4.9yrs	US$149.45k	0% € 0
Courtney Wallace	Independent Director	2.9yrs	US$164.59k	0% € 0
Micki Klearman	Independent Director	3.4yrs	US$161.58k	0% € 0

7.5yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 2KZ0 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.5 jaar).

Kezar Life Sciences Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Kezar Life Sciences, Inc., Annual General Meeting, Jun 18, 2024

Kezar Life Sciences, Inc. Announces CEO Changes

Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position

Kezar Life Sciences, Inc. Announces Executive Changes

Independent Director recently bought €1.2m worth of stock

Recent updates

Kezar Life Sciences Regain Compliance with Nasdaq Listing Rule 5550(a)(2)

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement Required to Maintain Continued Listing on the Nasdaq Capital Market

Concentra Biosciences, LLC cancelled the acquisition of Kezar Life Sciences, Inc. (NasdaqCM:KZR) from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others.

Concentra Biosciences, LLC submitted a non-binding proposal to acquire Kezar Life Sciences, Inc. (NasdaqCM:KZR) from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others for $80.3 million.

Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis

Kezar Life Sciences, Inc. Announces Cessation of Enrollment and Dosing in the Phase 2B Palizade Trial of Zetomipzomib in Active Lupus Nephritis Patients

Kezar Life Sciences, Inc. Provides Business Update

Kezar Life Sciences, Inc. to Transfer Its Listing to the Nasdaq Capital Market

Kezar Life Sciences, Inc., Annual General Meeting, Jun 18, 2024

Kezar Life Sciences Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Kezar Life Sciences, Inc. Announces CEO Changes

New minor risk - Market cap size

Kezar Life Sciences, Inc. Presents Positive Complete Results from the Mission Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis At the American College of Rheumatology Convergence 2022

Kezar Life Sciences, Inc. Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN's Kidney Week 2022 Annual Meeting

Kezar Life Sciences, Inc. Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis

Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position

Kezar Life Sciences, Inc. Announces Positive Topline Results from the Mission Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis

Kezar Life Sciences, Inc. Announces Executive Changes

Kezar Life Sciences, Inc. Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis

Independent Director recently bought €1.2m worth of stock

Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and Dermatomyositis

Kezar Life Sciences, Inc. Presents Results of the Completed MISSION Phase 1B Study of KZR-616 at EULAR 2021

New 90-day high: €5.45

New 90-day high: €5.10

Kezar Life Sciences, Inc. Provides Update on KZR-616: Selective Immunoproteasome Inhibitor and KZR-261: Protein Secretion Program

New 90-day high: €4.60

Kezar Highlights Data from Mission Phase 1B Study of Kzr-616 During the Pan American Congress of Rheumatology

Kezar Life Sciences, Inc. to Report Q2, 2020 Results on Aug 05, 2020

New 90-day low - €3.82

Kezar Life Sciences, Inc.(NasdaqGS:KZR) dropped from Russell 3000 Growth Index

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd